Efficacy of R‐BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy
Rory McCulloch(University Hospitals Plymouth NHS Trust), Simon Rule(University Hospitals Plymouth NHS Trust), Toby A. Eyre(Churchill Hospital), Annabel McMillan(University College London Hospitals NHS Foundation Trust), Francesca Maria Quaglia(University of Verona), Rebecca Frewin(Gloucestershire Hospitals NHS Foundation Trust), Nicola Crosbie(University Hospitals Plymouth NHS Trust), Jonathan Lambert(University College London Hospitals NHS Foundation Trust), Carlo Visco(University of Verona), Neil Phillips(University Hospitals of North Midlands NHS Trust), David Tucker(Royal Cornwall Hospital Trust)
Cited by 72
Related Papers
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|736
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682